Read by QxMD icon Read

Colon cancer subtype

Loukia G Karacosta, John C Fisk, Joseph Jessee, Swetha Tati, Bradley Turner, Diala Ghazal, Rachel Ludwig, Holly Johnson, Julia Adams, Munawwar Sajjad, Steven Koury, Rene Roy, James R Olson, Kate Rittenhouse-Olson
The tumor specificity of JAA-F11, a novel monoclonal antibody specific for the Thomsen-Friedenreich cancer antigen (TF-Ag-alpha linked), has been comprehensively studied by in vitro immunohistochemical (IHC) staining of human tumor and normal tissue microarrays and in vivo biodistribution and imaging by micro-positron emission tomography imaging in breast and lung tumor models in mice. The IHC analysis detailed herein is the comprehensive biological analysis of the tumor specificity of JAA-F11 antibody performed as JAA-F11 is progressing towards preclinical safety testing and clinical trials...
February 22, 2018: Translational Oncology
Seung Yoon Yang, Min Soo Cho, Nam Kyu Kim
Colorectal cancer is one of the most common malignancies in the world, and it exhibits differences in incidence, pathogenesis, molecular pathways, and outcome depending on the location of the tumor. Differences in the microbiome, clinical characteristics, and chromosomal and molecular characteristics have been reported between the right and left side of the colon. Areas covered: This review focuses on the latest developments in epidemiological and chromosomal and molecular studies, which have enhanced our understanding on the underlying genetic and immunological differences between the right-sided colon and the left-sided colorectum in metastatic colorectal cancer...
February 19, 2018: Expert Review of Anticancer Therapy
Hossein Molavi Vardanjani, AliAkbar Haghdoost, Kamran Bagheri-Lankarani, Maryam Hadipour
Background: Population aging and more prevalent westernized lifestyle would be expected to result in a markedly rising burden of colorectal cancer (CRC) in the future years. The aim of this study is to estimate the limited-time prevalence of CRC in Iran between 2015 and 2020. Materials and Methods: Aggregated CRC incidence data were extracted from the Iranian national cancer registry (IR.NCR) reports for 2003-2009 and from GLOBOCAN-2012 database for 2012. Incidence trends were analyzed by age groups, genders, histopathologic, and topographic subtypes to estimate annual percentage changes...
2018: Advanced Biomedical Research
Bingjun Bai, Lina Shan, Binbin Xie, Xuefeng Huang, Weifang Mao, Xiaowei Wang, Da Wang, Hongbo Zhu
KRAS mutations serve a function in tumorigenesis of colorectal cancer (CRC) and guide the use of targeted drugs. However, the prognostic value of KRAS mutations and their subtypes remain controversial. The present study aimed to investigate the correlations between KRAS mutations and clinicopathological characteristics, and their prognostic significance in Chinese patients with metastatic CRC (mCRC). A total of 135 patients with mCRC were analyzed for KRAS mutations. Mutations in codon 12 and 13 were identified in 45 (33...
March 2018: Oncology Letters
Barbara Frossi, Francesca Mion, Riccardo Sibilano, Luca Danelli, Carlo E M Pucillo
Mast cells (MCs) are derived from committed precursors that leave the hematopoietic tissue, migrate in the blood, and colonize peripheral tissues where they terminally differentiate under microenvironment stimuli. They are distributed in almost all vascularized tissues where they act both as immune effectors and housekeeping cells, contributing to tissue homeostasis. Historically, MCs were classified into 2 subtypes, according to tryptic enzymes expression. However, MCs display a striking heterogeneity that reflects a complex interplay between different microenvironmental signals delivered by various tissues, and a differentiation program that decides their identity...
March 2018: Immunological Reviews
Laiquan Huang, Kun He, Jianxin Wang, Jiawei Yan, Yizhi Jiang, Zhongling Wei, Jun Zhang, Guangxi Li, Dongping Huang
Eukaryotic translation initiation factors 3B (eIF3b) is a subtype of the eIF3 category, which has been verified to be over-expressed in colon cancer, bladder, prostate cancers and glioblastoma due to its impact on the cellular activity of cancer cells. However, no related research on exploring the correlation of eIF3b gene expression with cell proliferation and apoptosis in chronic myeloid leukemia (CML) has been conducted until now. Our study showed that the expression of eIF3b mRNA in CML patients was higher compared with nonmalignancy controls...
February 8, 2018: Oncology Research
Matthew Alderdice, Susan D Richman, Simon Gollins, Peter Stewart, Chris Hurt, Richard Adams, Amy McCorry, Aideen Roddy, Dale Vimalachandran, Claudio Isella, Enzo Medico, Tim Maughan, Darragh G McArt, Mark Lawler, Philip D Dunne
Colorectal cancer (CRC) biopsies underpin accurate diagnosis, but are also relevant for patient stratification in molecularly-guided clinical trials. The consensus molecular subtypes (CMS) and colorectal cancer intrinsic subtypes (CRIS) transcriptional signatures have potential clinical utility for improving prognostic/predictive patient assignment. However, their ability to provide robust classification, particularly in pre-treatment biopsies from multiple regions or at different time points remains untested...
February 7, 2018: Journal of Pathology
Frederick Allen, Iuliana D Bobanga, Peter Rauhe, Deborah Barkauskas, Nathan Teich, Caryn Tong, Jay Myers, Alex Y Huang
Inflammatory chemokines are critical contributors in attracting relevant immune cells to the tumor microenvironment and driving cellular interactions and molecular signaling cascades that dictate the ultimate outcome of host anti-tumor immune response. Therefore, rational application of chemokines in a spatial-temporal dependent manner may constitute an attractive adjuvant in immunotherapeutic approaches against cancer. Existing data suggest that the macrophage inflammatory protein (MIP)-1 family and related proteins, consisting of CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES), can be major determinant of immune cellular infiltration in certain tumors through their direct recruitment of antigen presenting cells, including dendritic cells (DCs) to the tumor site...
2018: Oncoimmunology
Dehao Yu, Peng Gao, Yongxi Song, Yuchong Yang, Xiaowan Chen, Yu Sun, Ailin Li, Zhenning Wang
Until now, it remains unclear how to best use the histological subtype in clinical practice. This study aimed to compare differences in the efficacy of postoperative chemotherapy among different histological subtypes of colon adenocarcinomas. Using the Surveillance, Epidemiology, and End Results-Medicare database, 51,200 patients with stage II or III primary colon carcinomas who underwent resection for curative intent between 1992 and 2008 were included. The survival benefit was evaluated using a Cox proportional hazards model, interaction analyses, and propensity score-matched techniques...
January 29, 2018: Cancer Medicine
Phattharaphon Wongphutorn, Chariya Chomvarin, Banchob Sripa, Wises Namwat, Kiatichai Faksri
BACKGROUND: Two-thirds of the world's population is thought to be infected by Helicobacter pylori. Although most people infected with H. pylori are asymptomatic, this pathogen is associated with several gastric pathologies including cancer. The risk factors for colonization are still unclear and the genetic diversity within individual hosts has never been clearly investigated. RESULT: This study determined the prevalence of, and explored risk factors for, H. pylori infection directly from paired saliva (n = 110) and stool (n = 110) samples from asymptomatic persons in Northeast Thailand...
January 30, 2018: BMC Microbiology
Carol Rouphael, Afrin Kamal, Madhusudhan R Sanaka, Prashanthi N Thota
Vitamin D has emerged as a promising anti-cancer agent due to its diverse biological effects on tumor differentiation, apoptosis and suppression of cellular proliferation. Current evidence suggests a protective role of vitamin D in colon cancer. The effect of vitamin D on esophageal cancer remains controversial. Multiple studies investigated the association between vitamin D and esophageal cancer, employing different modes of assessment of vitamin D status such as serum 25-hydroxyvitamin D levels, vitamin D dietary intake or exposure to ultraviolet B (UVB) radiation...
January 15, 2018: World Journal of Gastrointestinal Oncology
Natalia Glatzel-Plucinska, Aleksandra Piotrowska, Jedrzej Grzegrzolka, Mateusz Olbromski, Adam Rzechonek, Piotr Dziegiel, Marzenna Podhorska-Okolow
BACKGROUND: Non-small cell lung carcinomas (NSCLCs), mainly adenocarcinoma (AC) and squamous cell carcinoma (LSCC), account for about 80% of all lung cancer cases. One of the proteins involved in NSCLC progression may be special AT-rich binding protein 1 (SATB1), a potent transcriptional regulator, able to control the expression of whole sets of genes simultaneously. SATB1 has been found to be associated with aggressive phenotype and poor prognosis in numerous malignancies, including breast, colon, ovary and prostate cancer...
February 2018: Anticancer Research
Sameh Hany Emile, Alaa Magdy, Waleed Elnahas, Omar Hamdy, Mahmoud Abdelnaby, Wael Khafagy
BACKGROUND: Mucinous adenocarcinoma (MA) is a unique subtype of colorectal carcinoma. Although some investigators considered MA a predictor for poor prognosis, predictors for poor clinical outcome of MA were not elucidated. The present study aimed to investigate the predictors for local recurrence and distant metastasis of MA. METHODS: This was a retrospective review of patients with MA who underwent operation with curative intent. Variables included patient and tumor characteristics, TNM stage, investigations, details of surgery, and postoperative outcomes, including local recurrence and distant metastasis...
January 17, 2018: Surgery
Jessica Felton, Shien Hu, Jean-Pierre Raufman
BACKGROUND: Expression and activation of subtype-3 muscarinic receptors (M3R) plays an important role in the progression of colorectal neoplasia. METHODS: Herein, we describe the role of muscarinic receptors in colon cancer, focusing specifically on M3R, illustrate how M3R over-expression and activation of post-receptor signaling pathways potentiates tumor progression, and explore the efficacy and safety of a variety of therapeutic approaches that can target the molecules involved...
January 18, 2018: Current Molecular Pharmacology
Petra Jones, Janet E Cade, Charlotte E L Evans, Neil Hancock, Darren C Greenwood
Evidence on adherence to diet-related cancer prevention guidelines and associations with colorectal cancer (CRC) risk is limited and conflicting. The aim of this cohort analysis is to evaluate associations between adherence to the World Cancer Research Fund/American Institute of Cancer Research (WCRF/AICR) 2007 recommendations and incident CRC. The UK Women's Cohort Study comprises over 35 372 women who filled in a FFQ at baseline in 1995. They were followed up for CRC incidence for a median of 17·4 years, an individual score linking adherence to eight of the WCRF/AICR recommendations was constructed...
February 2018: British Journal of Nutrition
Aurelia Vattai, Vincent Cavailles, Sophie Sixou, Susanne Beyer, Christina Kuhn, Mina Peryanova, Helene Heidegger, Kerstin Hermelink, Doris Mayr, Sven Mahner, Christian Dannecker, Udo Jeschke, Bernd Kost
Introduction: RIP140 (Receptor Interacting Protein) is involved in the regulation of oncogenic signaling pathways and in the development of breast and colon cancers. The aim of the study was to analyze the expression of RIP140 and its partner LCoR in cervical cancers, to decipher their relationship with histone protein modifications and to identify a potential link with patient survival. Methods: Immunohistochemical analyses were carried out to quantify RIP140 and LCoR expression in formalin-fixed paraffin-embedded tissue sections cervical cancer samples...
December 1, 2017: Oncotarget
Pawel Karpinski, Joanna Rossowska, Maria Malgorzata Sasiadek
Recent, large-scale expression-based subtyping has advanced our understanding of the genomic landscape of colorectal cancer (CRC) and resulted in a consensus molecular classification that enables the categorization of most CRC tumors into one of four consensus molecular subtypes (CMS). Currently, major progress in characterization of immune landscape of tumor-associated microenvironment has been made especially with respect to microsatellite status of CRCs. While these studies profoundly improved the understanding of molecular and immunological profile of CRCs heterogeneity less is known about repertoire of the tumor infiltrating immune cells of each CMS...
December 1, 2017: Oncotarget
Jérôme Raffenne, Jérôme Cros
Multi-omics high throughput analyses lead to the description of multiple molecular subtypes of pancreatic adenocarcinoma with major prognostic impact for most of them. There is no consensual multilevel integrative classification yet like in colon or breast cancers. Genomic classifications have identified a tumor subtype (15% of the patients) with deficient homologous DNA repair-system leading to increase sensitivity to platinum-based therapies and possibly to PARP inhibitors and immunotherapies. Transcriptomic classifications are still debated but all have identified an aggressive subtype with a very poor prognosis, presumably unfit for a surgical approach...
December 19, 2017: Bulletin du Cancer
Tomohiro Aoki, Shuh Narumiya
Background: Colorectal cancer is the third most common cancer. Involvement of prostaglandin (PG) system in the pathogenesis of colorectal cancer has been suggested from clinical studies demonstrating therapeutic effect of NSAIDs including aspirin or selective COX-2 inhibitors. However, mechanisms on how PG regulates inflammatory responses leading to colorectal cancer development remain obscure. Further, careful attention is needed to use these drugs for a long time because of adverse effects due to non-specific inhibition of physiological PG production in addition to pathological one, making the development of alternatives to aspirin important...
2017: Inflammation and Regeneration
S Rim Kim, Nan Song, Greg Yothers, Patrick G Gavin, Carmen J Allegra, Soonmyung Paik, Katherine L Pogue-Geile
BACKGROUND: We tested the association of colon tumour sidedness with prognosis and with molecular subtypes recently shown to be predictive of oxaliplatin benefit in stage III colon cancer. METHODS: NSABP/NRG C-07 trial (N=1603) was used to determine association of tumour sidedness with molecular subtypes and recurrence-free survival (RFS) and overall survival (OS). RESULTS: Sidedness was associated with molecular subtypes except stem-like/CMS4 subtype...
December 14, 2017: British Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"